S1PR1 and COVID-19: Furthermore, sphingosine-1-phosphate receptor ligands (SRLs) may reduce lung damage in viral pneumonia, and ozanimod, a novel sphingosine-1-phosphate receptor ligand, has been recently studied in COVID-19 patients in a randomized open-label pilot trial (77).